Phase-1 Enters Marketing Deal with Axon Instruments | GenomeWeb

NEW YORK, Jan 23 – Phase-1 Molecular Toxicology, a privately held Santa Fe, N.M.–based toxicogenomics company, said Tuesday it has signed an agreement to sell Axon Instruments’ GenePx 4000B microarray scanner along with its toxicogenomic and toxicoproteomic microarrays and software.

The companies will offer the scanner, arrays, and software as a package deal, according to Phase-1 CEO Spencer Farr, who declined to specify how the companies will share revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.